Document Detail


Effect of the phosphodiesterase 4 inhibitor, rolipram, on retinoic acid-increased alkaline phosphatase activity in the mouse fibroblastic C3H10T1/2 cell line.
MedLine Citation:
PMID:  12615143     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We have evaluated effects of a phosphodiesterase (PDE) 4 inhibitor on retinoic acid-increased alkaline phosphatase activity in the mouse fibroblastic C3H10T1/2 clone 8 (10T1/2) cell line. 10T1/2 cells were cultured in minimum essential medium (MEM) and 10% fetal bovine serum with or without 1 microM retinoic acid and/or the PDE 4 inhibitor, rolipram, and harvested at specific intervals before measurement of alkaline phosphatase activity, cAMP production in response to parathyroid hormone, osteocalcin synthesis and expression, and phosphodiesterase activity. Retinoic acid-increased alkaline phosphatase activity, and slightly enhanced cAMP production in response to parathyroid hormone. However, it did not affect osteocalcin synthesis and expression. In the presence of retinoic acid, PDE 4 activity was not changed. A PDE 4 inhibitor, rolipram, and cAMP analog, 8-bromo-cAMP dramatically increased retinoic acid's ability to induce alkaline phosphatase activity. This is the first report that PDE 4 may be involved in regulation of retinoic acid-increased alkaline phosphatase activity.
Authors:
Taku Murata; Toshifumi Sugatani; Kasumi Shimizu; Vincent C Manganiello; Toshiro Tagawa
Related Documents :
11391073 - Alcohol and retinoids.
1292933 - Retinal oxidation activity and biological role of human cytosolic aldehyde dehydrogenase.
22706373 - Nir spectroscopic properties of aqueous acids solutions.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Archives of oral biology     Volume:  48     ISSN:  0003-9969     ISO Abbreviation:  Arch. Oral Biol.     Publication Date:  2003 Jan 
Date Detail:
Created Date:  2003-03-04     Completed Date:  2003-06-26     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0116711     Medline TA:  Arch Oral Biol     Country:  England    
Other Details:
Languages:  eng     Pagination:  63-7     Citation Subset:  D; IM    
Affiliation:
Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Mie University, 2-174 Edobashi, Tsu, 514-8507, Mie, Japan. muratat@clin.medic.mie-u.ac.jp <muratat@clin.medic.mie-u.ac.jp>
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
3',5'-Cyclic-AMP Phosphodiesterases / antagonists & inhibitors,  metabolism,  physiology
Alkaline Phosphatase / drug effects*,  metabolism
Animals
Cell Line
Cyclic AMP / biosynthesis
Cyclic Nucleotide Phosphodiesterases, Type 4
Drug Synergism
Fibroblasts / drug effects*,  enzymology
Mice
Osteocalcin / biosynthesis,  genetics
Parathyroid Hormone / pharmacology
Phosphodiesterase Inhibitors / pharmacology*
Rolipram / pharmacology*
Tretinoin / pharmacology*
Chemical
Reg. No./Substance:
0/Parathyroid Hormone; 0/Phosphodiesterase Inhibitors; 104982-03-8/Osteocalcin; 302-79-4/Tretinoin; 60-92-4/Cyclic AMP; 61413-54-5/Rolipram; EC 3.1.3.1/Alkaline Phosphatase; EC 3.1.4.17/3',5'-Cyclic-AMP Phosphodiesterases; EC 3.1.4.17/Cyclic Nucleotide Phosphodiesterases, Type 4

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Type II collagen and aggrecan mRNA expression by in situ hybridization in rabbit temporomandibular j...
Next Document:  Effects of alkaline phosphatase and its inhibitor levamisole on the modulation of androgen metabolis...